E-mail a Wiley Online Library Link

Jorge A. Garcia and Brian I. Rini Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead Cancer 118

Version of Record online: 28 OCT 2011 | DOI: 10.1002/cncr.26582

New chemotherapeutic approaches have demonstrated clinical benefit in the management of castration-resistant prostate cancer (CRPC), with novel adrenal androgen inhibitors also exhibiting antitumor activity. This review summarizes the current management of CRPC and discusses future directions.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field